The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Drynol 20 mg orodispersible tablets

Menarini International Operations Luxembourg S.A.PA0865/018/004

Main Information

Trade NameDrynol 20 mg orodispersible tablets
Active SubstancesBilastine
Dosage FormOrodispersible tablet
Licence HolderMenarini International Operations Luxembourg S.A.
Licence NumberPA0865/018/004

Group Information

ATC CodeR06AX29 bilastine


License statusAuthorised
Licence Issued03/03/2023
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back